Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Attacking lymphoma at the source

Non-Hodgkin lymphomas are cancers that affect white blood cells of the immune system called B-lymphocytes or B cells.

Like cells in all cancers, the B cells begin to grow out of control, creating tumours in the lymph nodes, spleen or other tissues.

In 2010 alone, it was estimated that non-Hodgkin lymphomas caused 210,000 deaths worldwide.

One of the driving forces behind non-Hodgkin lymphomas is the over-activation of a receptor on the surface of B cells.

This receptor normally stimulates the growth of B-cells only when it is needed, but in non-Hodgkin lymphoma, the growth signal is constantly on, making B-cells grow uncontrollably.

To block this signal, recent clinical studies have focused on inhibiting the activation of the B-cell receptor as a treatment for non-Hodgkin lymphoma patients, but with variable success.

For example, a drug called ibrutinib has been tested in clinical trials to treat an aggressive form of non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL).

Ibrutinib blocks the enzyme BTK (Bruton's tyrosine kinase), which is involved in maturing and activating B cells as part of the B-cell receptor's signalling pathway.

Unfortunately, the response to ibrutinib has been limited only to a subgroup of DLBCL patients.

The lab of Elisa Oricchio at EPFL has now carried out a study to identify mechanisms of resistance to ibrutinib.

Their findings are published in the journal Blood.

Using tumour cells from DLBCL patients, the scientists discovered that the inactivation of BTK in resistant tumours triggers the over-activation of alternative signals that promote tumour cell survival and proliferation.

To prevent this mechanism of resistance and block the B-cell receptor signalling at its root, Elena Battistello, the PhD student who led this project, targeted the three enzymes (LYN, FYN, and BLK) that initiate the propagation of the signals.

The scientists discovered that blocking these enzymes with a drug called masitinib completely ablated the B-cell receptor pro-tumorigenic signals.

In addition, masitinib strongly impaired tumour growth in all of the DLBCL patient-derived tissues that the team tested.

The authors, who are now planning to begin clinical trials based on this study, state that the three enzymes can be promising therapeutic targets for a diverse and broad group of DLBCL patients.

Source: EPFL

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence